<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="music/PMC3800126/results/search/drugs/results.xml">
  <result pre="non-responders. PTSD patients were provided with 10 weeks of open-label" exact="sertraline" post="and those who did not remit were then randomized"/>
  <result pre="were then randomized to either receive five additional weeks of" exact="sertraline" post="alone or with 10 sessions of twice weekly PE."/>
  <result pre="for patients who showed a partial response to phase I" exact="sertraline" post="treatment. PE augmentation was associated with lower PTSD severity"/>
  <result pre="an almost mirror design, no beneficial effects were found for" exact="paroxetine" post="enhancement when given in addition to PE to exposure"/>
  <result pre="2012) found that when the combination of exposure therapy and" exact="paroxetine" post="(an SSRI) was provided from the beginning of treatment,"/>
  <result pre="by follow-up. Even though initial treatment with exposure therapy and" exact="paroxetine" post="may lead to good clinical outcome, there are also"/>
  <result pre="rate and skin conductance in response to trauma script in" exact="propranolol" post="group. Yehuda et al. 2010 Hydrocortisone Veteran, male, N=2"/>
  <result pre="2010 Hydrocortisone Veteran, male, N=2 Controlled case study; 30 mg" exact="hydrocortisone" post="or placebo 30 minutes prior to 8 prolonged exposure"/>
  <result pre="Hydrocortisone: 43.0 Placebo: 52.0 Self-report (PSS-SR): more symptom decline in" exact="hydrocortisone" post="treated than placebo treated patient. Suris et al. 2010"/>
  <result pre="Suris et al. 2010 Hydrocortisone Veteran, male, N=20 RCT; 4mg/kg" exact="hydrocortisone" post="or placebo immediately after 1 memory reactivation session Traumatic"/>
  <result pre="1 session. N/A Self-report (IES-R): lower avoidance/numbing symptoms in the" exact="hydrocortisone" post="group compared to placebo. Brunet et al. 2011 Propranolol"/>
  <result pre="mixed trauma, N=28 Open label; 0.67 mg/kg short-acting+1 mg/kg long-acting" exact="propranolol" post="(modal dose resp. 40 and 60 mg), 90 minutes"/>
  <result pre="survivors, N=7 (treated) Open label; 40 mg short-acting+80 mg LA" exact="propranolol" post="90 minutes prior to session 1, 80 mg LA"/>
  <result pre="propranolol 90 minutes prior to session 1, 80 mg LA" exact="propranolol" post="90 minutes prior to sessions 2–6 Traumatic memory reactivation;"/>
  <result pre="extinction learning in rats previously exposed to the tricyclic antidepressant" exact="imipramine" post="(Werner-Seidler &amp;amp; Richardson, 2007), but no evidence was found"/>
  <result pre="receptor, and to a lesser extent to the release of" exact="norepinephrine" post="and dopamine (Johansen &amp;amp; Krebs, 2009; Sessa, 2008). MDMA"/>
  <result pre="to a lesser extent to the release of norepinephrine and" exact="dopamine" post="(Johansen &amp;amp; Krebs, 2009; Sessa, 2008). MDMA is known"/>
  <result pre="Second, MDMA might enhance extinction learning via enhanced cortisol and" exact="norepinephrine" post="levels. And a third, more indirect way, may be"/>
  <result pre="a third, more indirect way, may be that MDMA increases" exact="oxytocin" post="levels, which may strengthen the therapeutic alliance, and thereby"/>
  <result pre="the hypothesis that MDMA strengthens the therapeutic alliance via enhanced" exact="oxytocin" post="release. In both animal (Thompson, Callaghan, Hunt, Cornish, &amp;amp;"/>
  <result pre="2012) it was found that MDMA leads to higher blood" exact="oxytocin" post="levels, and in humans it was shown that blood"/>
  <result pre="oxytocin levels, and in humans it was shown that blood" exact="oxytocin" post="levels were strongly and positively correlated to subjective pro-social"/>
  <result pre="empirical data suggests that medication that inhibits serotonin (5-HT) and" exact="norepinephrine" post="(NE) uptake (respectively SSRI's and SNRI's), drugs commonly used"/>
  <result pre="indirectly via improvement of the therapeutic alliance due to heightened" exact="oxytocin" post="levels, the question arises whether direct administration of oxytocin"/>
  <result pre="heightened oxytocin levels, the question arises whether direct administration of" exact="oxytocin" post="would also enhance exposure therapy. Olff and colleagues ("/>
  <result pre="be more powerful than MDMA. Currently, Olff's group is examining" exact="oxytocin" post="enhancement of exposure therapy in refugees suffering from PTSD."/>
  <result pre="drug (&quot;ecstasy&quot;) is criminalized in most countries. The alternative of" exact="oxytocin" post="enhancement may have better clinical utility, considering that it"/>
  <result pre="memories (Aerni et al., 2004). Enhancement of exposure therapy with" exact="hydrocortisone" post="could be beneficial via both mechanisms: (1) enhanced consolidation"/>
  <result pre="2010). Two randomized studies provided support for exposure augmentation with" exact="hydrocortisone" post="in anxiety-disordered patients. Hydrocortisone given prior to exposure sessions"/>
  <result pre="clinical trials on the augmentation effects of exposure therapy with" exact="hydrocortisone" post="in PTSD patients. Two large scaled clinical studies by"/>
  <result pre="Yehuda and colleagues ( 2010) published a case study on" exact="hydrocortisone" post="enhancement in two male veterans suffering from severe PTSD"/>
  <result pre="depressive disorder. Participants were treated with PE therapy and either" exact="hydrocortisone" post="(30 mg, oral, 30 minutes prior to exposure session"/>
  <result pre="placebo (following the same time schedule). The patient who received" exact="hydrocortisone" post="improved more over the course of treatment than the"/>
  <result pre="design, Suris and colleagues ( 2010) investigated the effects of" exact="hydrocortisone" post="in 20 male veterans suffering from PTSD. Participants received"/>
  <result pre="in 20 male veterans suffering from PTSD. Participants received either" exact="hydrocortisone" post="(intravenous, 4 mg/kg) or placebo, directly after one exposure-based"/>
  <result pre="et al. found that, compared to placebo, participants who received" exact="hydrocortisone" post="had lower self-reported PTSD avoidance and numbing symptoms at"/>
  <result pre="and more lasting. Dosing, administration, adverse effects and contra-indications for" exact="hydrocortisone" post="enhancement Hydrocortisone can be administered orally, intramuscularly or intravenously."/>
  <result pre="a half-life of approximately 1.5 hours. Dosing and administration of" exact="hydrocortisone" post="given in supplementary fashion to exposure-based treatment in PTSD"/>
  <result pre="&amp;amp; Greene, 2010)]. In the two non-PTSD exposure enhancement trials," exact="hydrocortisone" post="was given three or four times, 60 minutes prior"/>
  <result pre="et al., 2011; Soravia et al., 2006). Low doses of" exact="hydrocortisone" post="(e.g., 10–30 mg once a week) do not cause"/>
  <result pre="2009). There is no need to physically monitor patients after" exact="hydrocortisone" post="intake. Besides the regular exclusion criteria for drug trials"/>
  <result pre="appear to be no major drug specific exclusion criteria for" exact="hydrocortisone" post="enhanced treatment relevant to the PTSD population. While participants"/>
  <result pre="medication are included. Discussion The evidence for beneficial effects of" exact="hydrocortisone" post="enhancement of exposure therapy in PTSD patients is very"/>
  <result pre="generalizes to PTSD patients. In PTSD patients, it appears that" exact="hydrocortisone" post="specifically affects avoidance symptoms. Avoidance has been implicated in"/>
  <result pre="al., 2010). Further, it is of interest to note that" exact="hydrocortisone" post="may have acute anxiolytic effects. A clinical trial in"/>
  <result pre="A clinical trial in patients with social phobia showed that" exact="hydrocortisone" post="(25 mg) given 1 hour prior to an exposure"/>
  <result pre="(Soravia et al., 2006). What the effect is of presession" exact="hydrocortisone" post="on fear levels during exposure therapy in PTSD patients,"/>
  <result pre="treatment efficacy, has yet to be established. The proposition that" exact="hydrocortisone" post="impairs retrieval of the traumatic memory targeted during an"/>
  <result pre="acceptability is of great relevance. Reflecting on its clinical utility," exact="hydrocortisone" post="seems safe, well tolerated and easy to administer. There"/>
  <result pre="exclusion criteria relevant to the PTSD population. So, albeit premature," exact="hydrocortisone" post="appears to be feasible to implement in routine clinical"/>
  <result pre="Squire, 1984). Indeed, experimental studies in non-clinical samples demonstrated that" exact="propranolol" post="has effects on memory reconsolidation (see for overview: Lonergan,"/>
  <result pre="2009) found that disruption of reconsolidation by oral administration of" exact="propranolol" post="resulted in diminished fear responses to conditioned stimuli. Even"/>
  <result pre="trial, Brunet and colleagues ( 2008) examined the effects of" exact="propranolol" post="given directly after one exposure-based session in 19 chronic"/>
  <result pre="19 chronic PTSD patients following mixed trauma. Participants received either" exact="propranolol" post="(40 mg short acting (SA) and 2 hours later"/>
  <result pre="i.e., facial frowning muscle) were measured. Participants who had received" exact="propranolol" post="postsession responded with lower heart rate and skin conductance"/>
  <result pre="on PTSD symptoms. There is support for the efficacy of" exact="propranolol" post="as a treatment enhancement strategy from three open-label studies"/>
  <result pre="28 patients with chronic PTSD following mixed trauma received six" exact="propranolol" post="enhanced exposure-based treatment sessions. Ninety minutes prior to the"/>
  <result pre="subsequent enhanced treatment sessions, participants received both SA and LA" exact="propranolol" post="90 minutes prior to the start of the session"/>
  <result pre="instead of a written account of the index trauma and" exact="propranolol" post="was given in fixed doses of 40 mg SA"/>
  <result pre="diagnostic criteria. In study 3, 32 participants self-selected to receive" exact="propranolol" post="enhanced treatment (N=7) or no treatment at all (N=25)."/>
  <result pre="protocol was similar to study 1 with slight differences in" exact="propranolol" post="dosing (see Table 1) and there was no administration"/>
  <result pre="line with the previous findings, for those participants who received" exact="propranolol" post="enhanced treatment, self-reported PTSD symptoms declined over time. Six"/>
  <result pre="the control group. Dosing, administration, adverse effects and contra-indications for" exact="propranolol" post="enhancement Propranolol lowers heart rate and relaxes blood vessels"/>
  <result pre="treatment of hypertension, angina pectoris, migraine and tremor. In addition," exact="propranolol" post="has anxiolytic effects (it reduces physical anxiety symptoms such"/>
  <result pre="240 mg daily, depending on treatment condition. In PTSD trials," exact="propranolol" post="was single dosed directly before or after exposure-based treatment"/>
  <result pre="ingestion and half-life is approximately 3–6 hours, while for LA" exact="propranolol" post="this is respectively 5 hours and between 10 and"/>
  <result pre="hours and between 10 and 20 hours. Adverse reactions to" exact="propranolol" post="appear to be dose related and include light headedness,"/>
  <result pre="sedation (Brunet et al., 2011). Propranolol is orally administered. Because" exact="propranolol" post="lowers blood pressure, in the Brunet trials blood pressure"/>
  <result pre="the Brunet trials blood pressure was monitored after the first" exact="propranolol" post="intake. If systolic blood pressure levels did not drop"/>
  <result pre="block or certain cardiac arrhythmias) were excluded from participation in" exact="propranolol" post="studies. Like propranolol, alcohol relaxes blood vessels, and simultaneous"/>
  <result pre="participants who used medication that could involve dangerous interactions with" exact="propranolol" post="were excluded from participation. Notably, this includes antidepressants that"/>
  <result pre="such as the SSRI paroxetine. Discussion Combined, the findings with" exact="propranolol" post="enhancement are promising and we await a placebo-controlled randomized"/>
  <result pre="promising and we await a placebo-controlled randomized clinical trial on" exact="propranolol" post="enhancement in PTSD patients. However, due to the uncontrolled"/>
  <result pre="PTSD patients. However, due to the uncontrolled methodology of the" exact="propranolol" post="treatment enhancement studies, the question of whether the observed"/>
  <result pre="question of whether the observed benefits were a consequence of" exact="propranolol" post="enhancement or the psychological intervention in itself remains unanswered."/>
  <result pre="proposed working mechanism, it is unclear from Brunet's studies whether" exact="propranolol" post="blocked fear-memory reconsolidation or, alternatively, enhanced extinction consolidation. Parsons"/>
  <result pre="enhanced extinction consolidation. Parsons &amp;amp; Ressler ( 2013) question whether" exact="propranolol" post="would succeed in reconsolidation blockage in PTSD patients, based"/>
  <result pre="will provide us with more information on the potential of" exact="propranolol" post="as a treatment enhancer in PTSD patients¯ Considering the"/>
  <result pre="a treatment enhancer in PTSD patients¯ Considering the feasibility of" exact="propranolol" post="for exposure treatment enhancement in PTSD patients, propranolol appears"/>
  <result pre="feasibility of propranolol for exposure treatment enhancement in PTSD patients," exact="propranolol" post="appears to be well tolerated and easy to administer."/>
  <result pre="cardiovascular problems, and alcohol use should be carefully monitored during" exact="propranolol" post="enhanced treatment, especially considering that alcohol abuse is a"/>
  <result pre="2006). PTSD patients who use SSRI's have been excluded from" exact="propranolol" post="enhancement studies (and will be excluded in upcoming trials,"/>
  <result pre="and the same research group conducted all the studies on" exact="propranolol" post="enhancement. For most enhancers the empirical evidence is still"/>
  <result pre="&amp;amp; Rothbaum, 1998), and Yehuda and colleagues ( 2010) added" exact="hydrocortisone" post="to PE therapy. This variation in exposure dose is"/>
  <result pre="symptoms) separately. The two reviewed studies on hydrocortisone, showed that" exact="hydrocortisone" post="appears to be beneficial primarily via diminishment of avoidance"/>
  <result pre="as a cognitive enhancer, the doses of DCS, hydrocortisone, and" exact="propranolol" post="are relatively low and infrequent, while adverse effects of"/>
  <result pre="antidepressants (SSRI's) is an exclusion criterion for enhancement studies with" exact="propranolol" post="and MDMA, generalizability of findings with these cognitive enhancers,"/>
  <result pre="www.clinicaltrials.gov; www.clinicaltrialsregister.eu) reveals that large(r) clinical trials on DCS (N&amp;gt;100)," exact="hydrocortisone" post="(N=60), and propranolol (N=50) enhancement in PTSD patients are"/>
  <result pre="that large(r) clinical trials on DCS (N&amp;gt;100), hydrocortisone (N=60), and" exact="propranolol" post="(N=50) enhancement in PTSD patients are currently enrolling patients."/>
  <result pre="Robertson K Nader K Pitman R. K Effect of post-retrieval" exact="propranolol" post="on psychophysiologic responding during subsequent script-driven traumatic imagery in"/>
  <result pre="S. P et al. Trauma reactivation under the influence of" exact="propranolol" post="decreases posttraumatic stress symptoms and disorder: 3 open-label trials"/>
  <result pre="K. T Rothbaum B Bell J et al. Efficacy of" exact="sertraline" post="in preventing relapse of posttraumatic stress disorder: Results of"/>
  <result pre="R Donders A. R Touw D. J et al. Increased" exact="oxytocin" post="concentrations and prosocial feelings in humans after ecstasy (3,4-methylenedioxymethamphetamine)"/>
  <result pre="3,4-methylenedioxymethamphetamine (MDMA, &quot;Ecstasy&quot;) are attenuated by the serotonin uptake inhibitor" exact="citalopram" post="Neuropsychopharmacology 2000 22 5 513 521 10731626 Litz B."/>
  <result pre="A review of safety, side-effects and subjective reactions to intranasal" exact="oxytocin" post="in human research Psychoneuroendocrinology 2011 36 8 1114 1126"/>
  <result pre="Langeland W Witteveen A Denys D A psychobiological rationale for" exact="oxytocin" post="in the treatment of posttraumatic stress disorder CNS Spectrum"/>
  <result pre="T Compton J Connor K. M et al. Augmentation of" exact="sertraline" post="with prolonged exposure in the treatment of posttraumatic stress"/>
  <result pre="J Amsel L et al. Combined prolonged exposure therapy and" exact="paroxetine" post="for PTSD related to the World Trade Center attack:"/>
  <result pre="E Cornish J. L McGregor I. S A role for" exact="oxytocin" post="and 5-HT(1A) receptors in the prosocial effects of 3,4"/>
  <result pre="Effects of D-cycloserine on extinction: Consequences of prior exposure to" exact="imipramine" post="Biological Psychiatry 2007 62 10 1195 1197 17555721 Yehuda"/>
 </snippets>
</snippetsTree>
